Core A - Resource for Clinical Studies of AKI

项目摘要 急性肾损伤(AKI)的临床和翻译研究需要获得具有良好特征的 纵向随访的患者，加上生物样本，使调查人员能够探测 影响结果的基本机制和途径。临床资源的具体目标 AKI(核心A)研究的目的是：(I)促进和支持AKI临床研究的设计和实施， 通过以下方式收集和记录患者详细表型特征的信息的适当工具 AKI的疗程，(Ii)提供对具有良好特征的患者的全面数据集的访问和 没有AKI，以及(Iii)提供包括人肾组织、血液和尿液的生物样本库， 链接到可访问的AKI患者和非AKI患者的临床数据库，以支持转化性研究 学习。这一核心将专门为调查人员提供访问AKI患者的途径 协助ICU持续登记AKI的国际合作调查人员网络 目前有超过2200名患者。核心A旨在促进假设驱动和 通过为临床研究和临床研究提供必要的资源来生成假设的临床研究 加强与以AKI为重点的全球大型调查人员和中心的互动。 自成立以来，核心一直非常成功地支持临床和 翻译研究。我们已经建立了一个强大的数据管理系统和患者数据库 Aki在适应个人研究人员的研究目标和合作方面是灵活的 中锋。Core A提供的一项新服务是增加了人类肾脏组织和生物 样本(血液、尿液和DNA)来自AKI患者和非AKI患者以及健康对照。在过去的4年里， 核心A在帮助临床研究的多个方面取得了很高的成效，支持了72名研究人员 包括8个试点和催化剂获奖者以及111个不同的项目。这些加在一起的努力已经导致了40 同行评议的出版物。我们的调查员基地正在利用核心A提供的所有服务。我们 设想这些丰富的资源将继续支持AKI的跨学科临床研究 促进我们对人类AKI的自然历史和病理生理学的理解。我们有信心 核心A与UAB和UCSD的现有资源以及奥布莱恩中心内的其他核心 将加快新的研究见解的转化，以改善AKI患者的预后。

Project Summary Clinical and translational research in acute kidney injury (AKI) requires access to well characterized patients with longitudinal follow up coupled with biological samples enabling investigators to probe the underlying mechanisms and pathways contributing to outcomes. The specific aims of the Resource for Clinical Studies of AKI (Core A) are to (i) facilitate and support the design and conduct of clinical research in AKI with appropriate tools to collect and record information for detailed phenotypic characterization of patients through the course of AKI, (ii) provide access to comprehensive datasets of well characterized patients with and without AKI, and (iii) provide a biological sample repository that includes human kidney tissue, blood and urine, linked to an accessible clinical database of patients with and without AKI to enable translational research studies. This core will specifically provide investigators access to patients with AKI through an established international network of collaborating investigators who are contributing to an ongoing registry of AKI in the ICU setting currently with over 2,200 patients. Core A is designed to facilitate both hypothesis-driven and hypothesis-generating clinical research by providing essential resources for clinical investigation and enhancing interactions with a large worldwide network of investigators and centers focused on AKI. Since its inception the Core has been very successful in supporting investigators for clinical and translational research. We have established a robust data management system and database of patients with AKI that is flexible in accommodating the research objectives of individual investigators and collaborating centers. A new service being offered by Core A is the addition of human kidney tissues along with biological samples (blood, urine and DNA) from patients with and without AKI and healthy controls. Over the last 4 years, Core A has been highly productive in assisting multiple facets of clinical research supporting 72 investigators including 8 pilot and catalyst awardees and 111 different projects. These combined efforts have resulted in 40 peer-reviewed publications. All services provided by Core A are being utilized by our investigator base. We envision that these rich resources will continue to enable interdisciplinary clinical investigation in AKI to advance our understanding of the natural history and pathophysiology of human AKI. We are confident that Core A in conjunction with the existing resources at UAB and UCSD and other cores within the O'Brien Center will accelerate the translation of new investigative insights towards improving outcomes for patients with AKI.